Avanos Medical Past Earnings Performance
Past criteria checks 0/6
Avanos Medical's earnings have been declining at an average annual rate of -58.9%, while the Medical Equipment industry saw earnings growing at 14.9% annually. Revenues have been declining at an average rate of 1.1% per year.
Key information
-58.93%
Earnings growth rate
-59.91%
EPS growth rate
Medical Equipment Industry Growth | 8.90% |
Revenue growth rate | -1.12% |
Return on equity | -45.29% |
Net Margin | -55.17% |
Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
Avanos Medical: Cheap, But With Caveats
Apr 17Avanos Medical (NYSE:AVNS) Has A Pretty Healthy Balance Sheet
Apr 08Lacklustre Performance Is Driving Avanos Medical, Inc.'s (NYSE:AVNS) Low P/S
Jan 30What Is Avanos Medical, Inc.'s (NYSE:AVNS) Share Price Doing?
Dec 18Avanos Medical, Inc.'s (NYSE:AVNS) Price Is Right But Growth Is Lacking
Oct 25There May Be Some Bright Spots In Avanos Medical's (NYSE:AVNS) Earnings
Aug 07Lacklustre Performance Is Driving Avanos Medical, Inc.'s (NYSE:AVNS) Low P/S
Apr 17Is Avanos Medical (NYSE:AVNS) A Risky Investment?
Jan 05Some Avanos Medical, Inc. (NYSE:AVNS) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 14When Should You Buy Avanos Medical, Inc. (NYSE:AVNS)?
Aug 13Avanos Medical: Leaning Up, Attractive Returns On Incremental Capital, Reiterate Buy
Jul 16We Think Avanos Medical (NYSE:AVNS) Can Manage Its Debt With Ease
Jun 05Avanos Medical, Inc. (NYSE:AVNS) Stocks Pounded By 26% But Not Lagging Market On Growth Or Pricing
May 18Avanos Medical (NYSE:AVNS) Is Looking To Continue Growing Its Returns On Capital
May 07Is Avanos Medical (NYSE:AVNS) Using Too Much Debt?
Mar 02Avanos Medical Q4 2022 Earnings Preview
Feb 20Avanos Medical, Inc. (NYSE:AVNS) Shares Could Be 30% Below Their Intrinsic Value Estimate
Feb 10Why Avanos Medical, Inc. (NYSE:AVNS) Could Be Worth Watching
Jan 13Avanos Medical reports Q3 mixed earnings; reaffirms FY22 guidance
Nov 02Avanos: Recent Entry To Hyaluronic Acid Market Sparks Interesting Debate
Sep 12Avanos Medical Q2 2022 Earnings Preview
Aug 08Revenue & Expenses Breakdown
How Avanos Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 25 | 689 | -380 | 314 | 11 |
31 Dec 24 | 688 | -386 | 321 | 12 |
30 Sep 24 | 682 | 22 | 313 | 13 |
30 Jun 24 | 682 | 7 | 298 | 12 |
31 Mar 24 | 680 | -2 | 315 | 12 |
31 Dec 23 | 673 | -10 | 321 | 13 |
30 Sep 23 | 682 | -11 | 326 | 13 |
30 Jun 23 | 683 | 9 | 346 | 14 |
31 Mar 23 | 684 | 18 | 336 | 15 |
31 Dec 22 | 684 | 22 | 327 | 29 |
30 Sep 22 | 696 | 23 | 332 | 15 |
30 Jun 22 | 708 | -23 | 332 | 16 |
31 Mar 22 | 723 | 10 | 326 | 17 |
31 Dec 21 | 587 | -31 | 257 | 31 |
30 Sep 21 | 736 | -52 | 327 | 10 |
30 Jun 21 | 738 | 2 | 334 | 10 |
31 Mar 21 | 715 | -38 | 334 | 9 |
31 Dec 20 | 715 | -29 | 327 | 35 |
30 Sep 20 | 720 | 14 | 354 | 16 |
30 Jun 20 | 705 | -17 | 366 | 18 |
31 Mar 20 | 714 | -22 | 384 | 19 |
31 Dec 19 | 698 | -46 | 373 | 38 |
30 Sep 19 | 678 | -42 | 389 | 40 |
30 Jun 19 | 671 | -27 | 376 | 41 |
31 Mar 19 | 660 | -17 | 354 | 42 |
31 Dec 18 | 652 | -8 | 327 | 42 |
30 Sep 18 | 649 | -1 | 313 | 43 |
30 Jun 18 | 634 | -16 | 310 | 42 |
31 Mar 18 | 622 | -28 | 318 | 41 |
31 Dec 17 | 612 | -32 | 322 | 38 |
30 Sep 17 | -171 | -150 | 290 | 35 |
30 Jun 17 | 76 | -130 | 311 | 37 |
31 Mar 17 | 327 | -112 | 338 | 37 |
31 Dec 16 | 566 | -83 | 346 | 38 |
30 Sep 16 | 1,584 | 44 | 421 | 17 |
30 Jun 16 | 1,576 | -435 | 418 | 16 |
31 Mar 16 | 1,565 | -434 | 416 | 13 |
31 Dec 15 | 509 | -101 | 350 | 28 |
30 Sep 15 | 1,612 | -443 | 444 | 13 |
30 Jun 15 | 1,631 | 20 | 458 | 11 |
31 Mar 15 | 1,656 | 7 | 460 | 14 |
31 Dec 14 | 1,672 | 27 | 442 | 17 |
30 Sep 14 | 1,664 | 69 | 383 | 40 |
30 Jun 14 | 1,675 | 125 | 354 | 40 |
Quality Earnings: AVNS is currently unprofitable.
Growing Profit Margin: AVNS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AVNS is unprofitable, and losses have increased over the past 5 years at a rate of 58.9% per year.
Accelerating Growth: Unable to compare AVNS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVNS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15.1%).
Return on Equity
High ROE: AVNS has a negative Return on Equity (-45.29%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/22 06:41 |
End of Day Share Price | 2025/05/22 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Avanos Medical, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ravi Misra | Berenberg |
Daniel Stauder | Citizens JMP Securities, LLC |
Kristen Stewart | Deutsche Bank |